2. Search Result
Search Result
Results for "

oral administration

" in MedChemExpress (MCE) Product Catalog:

148

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

11

Natural
Products

6

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100897
    Sulodexide

    		Thrombin Cardiovascular Disease
    Sulodexide is a mixture of glycosaminoglycans available in soft capsule form for oral administration. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease . Sulodexide is a glycosaminoglycan mixture available in soft gelatin capsule form for oral administration.
    Sulodexide
  • HY-114452
    LY2940094
    1 Publications Verification

    BTRX-246040

    		 Opioid Receptor Neurological Disease
    LY2940094 (BTRX-246040) is a potent, selective and orally available nociceptin receptor (NOP receptor) antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 reduces ethanol self-administration in animal models .
    LY2940094
  • HY-N6641
    Monascin
    2 Publications Verification

    		 Keap1-Nrf2 PPAR Inflammation/Immunology Cancer
    Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist .
    Monascin
  • HY-19929
    Tanimilast

    CHF-6001

    		 Phosphodiesterase (PDE) NF-κB Interleukin Related CXCR CCR TNF Receptor Inflammation/Immunology
    Tanimilast (CHF-6001) is an orally active and selective phosphodiesterase 4 inhibitor (IC50=0.026 nM) with robust anti-inflammatory activity and suitable for topical pulmonary administration. Tanimilast increases cellular cAMP levels, and inhibits NF-κB signaling pathway. Tanimilast is used for the research of obstructive lung diseases .
    Tanimilast
  • HY-118189
    Misoprostol acid
    1 Publications Verification

    		 Prostaglandin Receptor Inflammation/Immunology
    Misoprostol acid is an active metabolite of Misoprostol. Misoprostol is a synthetic analogue of prostaglandin E1 (PGE1), extensively absorbed, and undergoes rapid de-esterification to Misoprostol acid in the gastrointestinal tract after oral administration. Misoprostol can be used for non-steroidal anti-inflammatory drug-induced (NSAID) gastric ulcers . Misoprostol is an oral agent used to induce labor .
    Misoprostol acid
  • HY-16100
    BI 99179
    3 Publications Verification

    		 Fatty Acid Synthase (FASN) Metabolic Disease Cancer
    BI 99179, a chemical probe, is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC50 of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats .
    BI 99179
  • HY-164782
    PT3

    		HDAC Neurological Disease Metabolic Disease Cancer
    PT3 is a selective inhibitor of HDAC3 with an IC50 value of 0.25 μM. PT3 exhibits good brain penetration ability and bioavailability upon oral administration. PT3 can be used in the research of Alzheimer’s disease .
    PT3
  • HY-114452A
    LY2940094 tartrate
    1 Publications Verification

    BTRX-246040 tartrate

    		 Opioid Receptor Neurological Disease
    LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models .
    LY2940094 tartrate
  • HY-101478
    Fenobam

    		mGluR Apoptosis Neurological Disease Cancer
    Fenobam is a selective and orally active mGluR5 antagonist (IC50=84 nM) that can penetrate the blood-brain barrier. Fenobam shows the Kd values of 54 nM and 31 nM on rat and human recombinant mGlu5 receptors, respectively. Fenobam has anxiolytic activity, inhibits self-administration behavior in mice, and induces apoptosis in cancer cells. Fenobam can be used for research on neurological diseases, cancer and drug addiction .
    Fenobam
  • HY-W013762
    Tributyl citrate

    		Environmental Pollutants Biochemical Assay Reagents Others
    Tributyl citrate is a low-toxicity and orally active citrate ester with no genotoxicity or skin sensitizing activity. Tributyl citrate also acts as a plasticizer, solvent, FDA-approved indirect food additive, and topical anesthetic, among other uses. Tributyl citrate induces a needle-prick insensitivity response that lasts for more than 2 hours, and a 5% suspension of it temporarily eliminates the corneal reflex in rabbits. Tributyl citrate causes no significant systemic toxicity in rats and cats at most tested doses, and only may cause growth retardation and gastrointestinal reactions such as diarrhea and nausea at high doses or with repeated oral administration .
    Tributyl citrate
  • HY-18060
    Bradanicline

    TC-5619

    		 nAChR Neurological Disease
    Bradanicline (TC-5619) is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .
    Bradanicline
  • HY-108288
    Sulbactam pivoxil

    Pivsulbactam; CP 47904

    		 Beta-lactamase Antibiotic Bacterial Infection
    Sulbactam pivoxil (Pivsulbactam) is a prodrug of Sulbactam (HY-B0334) with oral activity. Sulbactam is a β-lactamase inhibitor with antibacterial activity. Sulbactam pivoxil is better absorbed than Sulbactam and results in higher serum levels after oral administration .
    Sulbactam pivoxil
  • HY-A0234
    Stepronin
    2 Publications Verification

    Prostenoglycine; TTPG; Tiase

    		 Chloride Channel Endocrinology
    Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin
  • HY-N0856
    Alisol C 23-acetate

    23-O-Acetylalisol C; Alisol C monoacetate

    		 Others Cardiovascular Disease
    Alisol C 23-acetate, a natural product extracted from Alisma orinentale, can significantly and strongly inhibit DTH response after oral administration.
    Alisol C 23-acetate
  • HY-W011309
    1-O-Hexadecylglycerol

    1-O-HDG; HXDG

    		 PPAR PGE synthase Inflammation/Immunology
    1-O-Hexadecylglycerol can up-regulate PPAR-γ expression, inhibit pGE2, and exhibit anti-inflammatory properties . 1-O-Hexadecylglycerol is effective in oral administration .
    1-O-Hexadecylglycerol
  • HY-14826
    Tilivapram

    AVE8112

    		 Phosphodiesterase (PDE) Neurological Disease
    Tilivapram (AVE8112) is an orally active PDE4 inhibitor with procognitive effects. Tilivapram exhibits in vivo efficacy and improves processing speed and psychomotor speed. Oral administration of tilivapram may induce dose-related adverse reactions such as nausea and dizziness, but transdermal delivery enables slow, controlled elevation of plasma concentrations, thereby significantly reducing gastrointestinal discomfort and dizziness. Tilivapram is applicable to research related to neuropsychiatric disorders .
    Tilivapram
  • HY-15883
    GNE-900

    		Checkpoint Kinase (Chk) Apoptosis Cancer
    GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 μM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. Gemcitabine (HY-17026) and GNE-900 administration shows anti-tumor activity .
    GNE-900
  • HY-N10225
    Thielavin A

    		Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Thielavin A is an inhibitor of prostaglandin biosynthesis produced by Thielavia terricola. Thielavin A specifically inhibits the conversion of arachidonic acid into prostaglandin H2. Thielavin A has no anti-inflammatory activity on intravenous injection or on oral administration .
    Thielavin A
  • HY-135578
    Artelinic acid

    		Parasite Infection
    Artelinic acid, a derivative of Artemisinin, is an antimalarial agent for the treatment of multidrug resistant strains of Plasmodium falciparum. Artelinic acid can be administered by various routes of administration, including intravenous, intramuscular and oral routes .
    Artelinic acid
  • HY-165529
    Camostat
    Maximum Cited Publications
    43 Publications Verification

    		 Ser/Thr Protease Inflammation/Immunology
    Camostat is an orally active trypsin inhibitor. Camostat can reduce pancreatic fibrosis induced by repeated administration of superoxide dismutase inhibitors in rats, and decrease the proliferation and activation of pancreatic stellate cells (PSCs) .
    Camostat
  • HY-103442
    CGP52411
    1 Publications Verification

    DAPH

    		 EGFR Amyloid-β Neurological Disease Cancer
    CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca 2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease .
    CGP52411
  • HY-100085
    21-Desacetyldeflazacort

    21-desDFZ

    		 Drug Metabolite Inflammation/Immunology
    21-Desacetyldeflazacort (21-desDFZ) is the active metabolite of Deflazacort (HY-13609). Deflazacort is an anti-inflammatory and immunosuppressant. Deflazacort is an inactive pro-drug which can be rapidly converted by esterases to the active metabolite 21-desacetyldeflazacort after oral administration .
    21-Desacetyldeflazacort
  • HY-167840
    IMMH-010 maleate

    		PD-1/PD-L1 Neurological Disease Cancer
    IMMH-010 maleate is a prodrug that serves as a novel PD-L1 inhibitor, exhibiting potential antitumor activity for the treatment of neurological disorders and advanced malignant solid tumors. IMMH-010 maleate is rapidly converted to its active form, YPD-29B, following oral administration. IMMH-010 maleate is poised for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.
    IMMH-010 maleate
  • HY-B0967
    Phthalylsulfacetamide

    		Bacterial Infection
    Phthalylsulfacetamide is a sulfa drug, after oral administration, slowly decompose in the intestine,and release sulfacetamide ,generating antibacterial effect.
    Phthalylsulfacetamide
  • HY-145461
    Hydroxy lenalidomide

    5-Hydroxy lenalidomide

    		 Drug Metabolite Others
    Hydroxy lenalidomide (5-Hydroxy lenalidomide) is a metabolite of lenalidomide that is present as a minor component in plasma and excreta, accounting for less than 5% of the total radioactivity, following oral administration of lenalidomide in healthy male subjects.
    Hydroxy lenalidomide
  • HY-N4173
    8-Oxoepiberberine

    		Drug Metabolite Metabolic Disease
    8-Oxoepiberberine is an alkaloid metabolite in the plasma after oral administration of Zuojin formula, a traditional chinese medicine used to treat gastrointestinal disease .
    8-Oxoepiberberine
  • HY-118426
    (Rac)-Tipifarnib

    (Rac)-IND 58359; (Rac)-R115777

    		 Farnesyl Transferase Ras Cancer
    (Rac)-Tipifarnib ((Rac)-IND 58359; (Rac)-R115777) is a potent farnesyl protein transferase inhibitor that specifically targets the pro-tailation process of Ras proteins. (Rac)-Tipifarnib showed significant in vivo antitumor effects after oral administration to mice .
    (Rac)-Tipifarnib
  • HY-108288R
    Sulbactam pivoxil (Standard)

    Pivsulbactam (Standard); CP 47904 (Standard)

    		 Beta-lactamase Reference Standards Antibiotic Bacterial Infection
    Sulbactam pivoxil (Standard) (Pivsulbactam (Standard)) is the analytical standard of Sulbactam pivoxil (HY-108288). This product is intended for research and analytical applications. Sulbactam pivoxil (Pivsulbactam) is a prodrug of Sulbactam (HY-B0334) with oral activity. Sulbactam is a β-lactamase inhibitor with antibacterial activity. Sulbactam pivoxil is better absorbed than Sulbactam and results in higher serum levels after oral administration .
    Sulbactam pivoxil (Standard)
  • HY-U00122
    Antiulcer Agent 1

    		Drug Derivative Inflammation/Immunology
    Antiulcer Agent 1 is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new agent development.
    Antiulcer Agent 1
  • HY-N14880
    Oudenone

    		Antibiotic Bacterial Infection Cardiovascular Disease
    Oudenone is an oxygen-containing heterocyclic antibiotic. Oudenone has weak antibacterial and fungal activity. Oudenone has antihypertensive effect on spontaneous hypertension in rats by intraperitoneal injection or oral administration .
    Oudenone
  • HY-123186
    MB-11362

    RG-7348

    		 HCV Infection
    MB-11362 is an orally active, selective HCV NS5B polymerase inhibitor and 4′-azidouridine triphosphate prodrug. MB-11362 can be converted to 4′-azidouridine triphosphate after oral administration. MB-11362 can be used in the research of HCV infection .
    MB-11362
  • HY-12096
    WAY-207024

    		GnRH Receptor Endocrinology
    WAY-207024 is an orally active gonadotropin releasing hormone receptor (GnRH-R) antagonist (human GnRH: IC50 of 12 nM, rat GnRH: IC50 of 71 nM). WAY-207024 inhibits rat LH release with an IC50 of 350 nM. WAY-207024 lowers rat plasma leuteinizing hormone (LH) levels after oral administration .
    WAY-207024
  • HY-122968
    Brocresine

    NSD-1065

    		 Endogenous Metabolite Neurological Disease
    Brocresine (NSD-1065) is an orally active histidine decarboxylase inhibitor and inhibits the formation of histamine from histidine. Brocresine is also a L-amino acid decarboxylase inhibitor with both a peripheral and central action. Brocresine inhibits gastric secretory response to administration of exogenous gastrin .
    Brocresine
  • HY-111073
    Bentysrepinine

    Y101

    		 HBV Infection Inflammation/Immunology
    Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields .
    Bentysrepinine
  • HY-145427
    NU5455

    		DNA-PK Cancer
    NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .
    NU5455
  • HY-105215
    FK888

    		Neurokinin Receptor Inflammation/Immunology
    FK888 is a potent, selective, and high affinity dipeptide NK1 receptor antagonist. FK888 displaces [3H]-SP binding with a Ki value of 0.69 nM and 0.45 microM. FK888 also inhibits SP-induced airway oedema in guinea-pig after both intravenous and oral administration .
    FK888
  • HY-159489
    SDUY038

    		SHP2 Cancer
    SDUY038 is a SHP2 allosteric inhibitor, with an IC50 of 1.2 μM and KD of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC50 = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t1/2 of 3.95 h by oral administration .
    SDUY038
  • HY-107129
    MK-3577

    		GCGR Metabolic Disease
    MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .
    MK-3577
  • HY-162423
    CYB210010

    		5-HT Receptor Androgen Receptor Neurological Disease
    CYB210010 is an orally bioavailable, long-acting serotonin 5-HT2 receptor agonist that selectively targets 5-HT2A and 5-HT2C receptors (EC50: 4.1 n, 7.3 nM). CYB210010 can enter the central nervous system, cause a head twitch response (HTR), and is not prone to behavioral tolerance during chronic administration .
    CYB210010
  • HY-146012
    HIV-1 protease-IN-4

    		HIV Infection
    HIV-1 protease-IN-4 (Compound II-22) is a potent HIV-1 protease inhibitor. HIV-1 protease-IN-4 is a proagent of atazanavir. HIV-1 protease-IN-4 as a proagent that delivers the parent 1 to rat plasma with a 5-fold higher AUC and 67-fold higher C24 when compared to oral administration of the parent agent .
    HIV-1 protease-IN-4
  • HY-126835
    A924

    		Amino Acid Derivatives Cancer
    A 924 is an amino acid derivative-based, orally active antitumor agent. A 924 is effective in inhibiting ascites tumors in rat models by intraperitoneal injection or oral administration. The LD50 of A 924 in mice is >1.5 g/kg and >4.5 g/kg by intraperitoneal injection or oral administration, respectively. A 924 does not cause teratogenicity or adverse reactions in normal or pregnant mice .
    A924
  • HY-A0234R
    Stepronin (Standard)

    Prostenoglycine (Standard); TTPG (Standard); Tiase (Standard)

    		 Chloride Channel Reference Standards Endocrinology
    Stepronin (Standard) is the analytical standard of Stepronin. This product is intended for research and analytical applications. Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl - secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin (Standard)
  • HY-W031110
    2-Methyl-tetrahydro-β-carboline

    2-MTHBC

    		 Drug Metabolite Neurological Disease
    2-Methyl-tetrahydro-β-carboline is a cyclization product of N,N-dimethyltryptamine after oral administration of ayahuasca .
    2-Methyl-tetrahydro-β-carboline
  • HY-W740380
    21-Carboxylic acid triamcinolone acetonide

    		Drug Metabolite Others
    21-Carboxylic acid triamcinolone acetonide is a metabolite produced in the body after oral administration of [14C]-triamcinolone acetonide .
    21-Carboxylic acid triamcinolone acetonide
  • HY-W758934
    Stepronin-d5

    Prostenoglycine-d5; TTPG-d5; Tiase-d5

    		 Isotope-Labeled Compounds Chloride Channel Endocrinology
    Stepronin-d5 (Prostenoglycine-d5; TTPG-d5; Tiase-d5) is the deuterium labeled Stepronin (HY-A0234). Stepronin (Prostenoglycine) is an orally active expectorant (inhalation administration is preferable to oral administration). Stepronin inhibits airway secretion in vitro by reducing Cl- secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands .
    Stepronin-d5
  • HY-122307
    Sulisatin

    DAN-603

    		 Bacterial Metabolic Disease
    Sulisatin (DAN-603) is an anionic laxative that is hydrolyzed to diphenolic derivatives by bacterial aryl sulfate sulfohydrolases in the colon during oral administration .
    Sulisatin
  • HY-120639
    BMS-663749 lysine

    		HIV Others
    BMS-663749 lysine is a prodrug of an HIV-1 attachment inhibitor with the potential to enhance the delivery of the parent compound following oral administration.
    BMS-663749 lysine
  • HY-118543
    TM6089

    		HIF/HIF Prolyl-Hydroxylase Cardiovascular Disease
    TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector .
    TM6089
  • HY-135245
    Ezetimibe hydroxy glucuronide

    SCH 488128; Ezetimibe hydroxy β-D-Glucuronide

    		 Drug Metabolite Cardiovascular Disease
    Ezetimibe hydroxy glucuronide (SCH 488128) is a trace metabolite detected in dog and human plasma samples after oral administration of Ezetimibe (HY-17376) .
    Ezetimibe hydroxy glucuronide
  • HY-105919
    Naroparcil

    		Factor Xa Cardiovascular Disease
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
    Naroparcil

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: